Who are LM-108 in combination with Toripalimab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lm-108-in-combination-with-toripalimab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

LM-108 in combination with Toripalimab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LM-108 in combination with Toripalimab (LM-108 in combination with Toripalimab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunotherapy combination (checkpoint inhibitor + unknown immunomodulator). Area: Oncology.

phase 3 Immunotherapy combination (checkpoint inhibitor + unknown immunomodulator) PD-1 (Toripalimab); LM-108 target unknown Oncology Small molecule Live · refreshed every 30 min

Target snapshot

LM-108 in combination with Toripalimab (LM-108 in combination with Toripalimab) — LaNova Medicines Limited. LM-108 combined with Toripalimab works by blocking immune checkpoints to enhance anti-tumor immunity, with LM-108 targeting a specific immune pathway while Toripalimab blocks PD-1.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LM-108 in combination with Toripalimab TARGET	LM-108 in combination with Toripalimab	LaNova Medicines Limited	phase 3	Immunotherapy combination (checkpoint inhibitor + unknown immunomodulator)	PD-1 (Toripalimab); LM-108 target unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunotherapy combination (checkpoint inhibitor + unknown immunomodulator) class)

LaNova Medicines Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LM-108 in combination with Toripalimab — Competitive Intelligence Brief. https://druglandscape.com/ci/lm-108-in-combination-with-toripalimab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab